PLACE OF TICAGRELOR IN THE NEW RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
This article presents the main results of large clinical studies that explored the efficacy and safety of antiplatelet agent, P2Y12 inhibitor, ticagrelor. The PLATO, ATLANTIC and PAGASUS-TIMI-54 studies' results formed the basis for inclusion of ticagrelor in the clinical recommendations for th...
Saved in:
Main Author: | A. D. Ehrlich (Author) |
---|---|
Format: | Book |
Published: |
«REMEDIUM GROUP» Ltd.,
2015-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Critical appraisal of ticagrelor in the management of acute coronary syndrome
by: Nawarskas JJ, et al.
Published: (2011) -
Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada
by: Grima DT, et al.
Published: (2014) -
Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?
by: Ibrahim Akin, et al.
Published: (2022) -
Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
by: Peixun He, et al.
Published: (2021) -
Efficacy and safety outcomes of ticagrelor compared with clopidogrel in Chinese elderly patients with acute coronary syndrome
by: Wang HD, et al.
Published: (2016)